载脂蛋白A-II水平降低因果性导致脓毒性休克死亡率增加
该研究在687例日本脓毒性休克患者中分析入院时脂蛋白及载脂蛋白水平与院内死亡的关系,并在474例高加索脓毒性休克队列(VASST)中验证。结果显示载脂蛋白A-II水平降低与脓毒性休克死亡率增加相关(校正OR 1.05,95%CI 1.02-1.09,P<0.001);ApoA2基因rs6413453 GG携带者28天死亡率更高(aHR 1.79,95%CI 1.06-3.04,P=0.029),且无心血管、呼吸、肾脏和神经功能障碍的天数更少,该结果在高加索队列中得到重复(28天死亡率aHR 1.65,95%CI 1.02-2.68,P=0.041)。基于9个SNP的孟德尔随机化提示遗传决定的载脂蛋白A-II水平降低是脓毒性休克死亡率增加的因果因素(载脂蛋白A-II每降低1 mg/dL的死亡OR 1.05,95%CI 1.01-1.03,P=0.0022)。
要点
- 日本脓毒性休克队列中,入院时载脂蛋白A-II水平降低与院内死亡增加独立相关(校正OR 1.05,95%CI 1.02-1.09,P<0.001)。
- ApoA2基因rs6413453 GG携带者28天死亡率显著高于AG/AA携带者(aHR 1.79,95%CI 1.06-3.04,P=0.029),且无心血管、呼吸、肾脏和神经功能障碍的天数更少。
- 上述28天死亡率关联在高加索脓毒性休克队列(VASST,n=474)中得到重复(aHR 1.65,95%CI 1.02-2.68,P=0.041)。
- 孟德尔随机化分析提示遗传决定的载脂蛋白A-II水平降低是脓毒性休克死亡率增加的因果因素(载脂蛋白A-II每降低1 mg/dL的死亡OR 1.05,95%CI 1.01-1.03,P=0.0022)。
适用人群与场景
- 日本脓毒性休克患者687例,入院时(进入ICU时)检测脂蛋白及载脂蛋白水平。
- 高加索脓毒性休克患者474例(VASST队列)用于重复验证。
研究设计与关键结果
- 研究类型:在687例日本脓毒性休克患者中分析入院时脂蛋白/载脂蛋白水平与院内死亡的关系,并检测候选基因变异与28天死亡率及器官功能障碍的关联;在高加索脓毒性休克队列(VASST,n=474)中重复验证;采用基于日本队列GWAS多基因评分的孟德尔随机化分析判断因果贡献。
- 日本队列:载脂蛋白A-II水平降低与脓毒性休克死亡率增加相关(校正OR 1.05,95%CI 1.02-1.09,P<0.001)。
- ApoA2基因rs6413453 GG携带者28天死亡率显著高于AG/AA携带者(aHR 1.79,95%CI 1.06-3.04,P=0.029),且无心血管、呼吸、肾脏和神经功能障碍的天数显著少于AG/AA携带者。
- 高加索脓毒性休克队列重复验证:rs6413453 GG携带者28天死亡率aHR 1.65(95%CI 1.02-2.68,P=0.041)。
- 孟德尔随机化(基于载脂蛋白A-II GWAS的9个SNP)提示遗传决定的载脂蛋白A-II水平降低是脓毒性休克死亡率增加的因果因素(载脂蛋白A-II每降低1 mg/dL的死亡OR 1.05,95%CI 1.01-1.03,P=0.0022)。
证据类型、等级与局限
- 证据类型:队列研究(日本队列687例,高加索验证队列VASST 474例)结合孟德尔随机化分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒性休克中,载脂蛋白A-II水平和ApoA2基因变异是与结局相关的重要因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lipoproteins and their component apolipoproteins play an important role in sepsis. However, little is known with regard to the association and causal contribution of these proteins to mortality in patients of different ancestries following septic shock. The objective of this study was to determine whether lipoprotein and apolipoprotein levels, and related genetic variants, are associated with clinical outcomes in septic shock.
METHODS: We investigated the association between lipoprotein and apolipoprotein levels at the point of admission to the intensive care unit and in-hospital mortality in 687 Japan patients diagnosed with septic shock. For each clinically significant candidate protein, we extracted haplotype tag single nucleotide polymorphisms (SNPs) of the corresponding gene and examined the association of the candidate gene variants with 28-day mortality and organ dysfunction. We tested for replication in a Caucasian septic shock cohort (Vasopressin and Septic Shock Trial, VASST, n = 474). To determine whether the candidate lipoprotein causally contributed to septic shock outcome, we used a Mendelian randomization analysis based on polygenic scores generated from a genome-wide association study (GWAS) in the Japan cohort.
RESULTS: In the Japan cohort, low apolipoprotein A-II levels were associated with increased septic shock mortality (adjusted odds ratio, 1.05; 95%CI, 1.02-1.09; P < 0.001). For a haplotype tag SNP of the corresponding ApoA2 gene, rs6413453 GG carriers had significantly higher 28-day mortality (adjusted hazard ratio [aHR], 1.79; 95% confidence interval [CI], 1.06-3.04; P = 0.029) and significantly fewer days free of cardiovascular, respiratory, renal and neurologic dysfunction than AG/AA carriers. This result was replicated in the Caucasian septic shock cohort (28-day mortality: aHR, 1.65; 95% CI, 1.02-2.68; P = 0.041). Mendelian randomization using 9 SNPs from an apolipoprotein A-II GWAS suggested that genetically decreased levels of apolipoprotein A-II were a causal factor for increased mortality in septic shock (odds ratio for mortality due to a 1 mg/dL decrease in apolipoprotein A-II is 1.05 [95% CI; 1.01-1.03, P = 0.0022]).
CONCLUSIONS: In septic shock, apolipoprotein A-II levels and ApoA2 genetic variations are important factors associated with outcome.
参考来源
- Takahashi N, Campbell KR, Shimada T, et al. Low apolipoprotein A-II levels causally contribute to increased mortality in septic shock. J Intensive Care. 2025. PMID: 39980010. doi:10.1186/s40560-025-00782-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。